Home / Filing changes / GILD
Free · no account · quoted from the filing
What changed in GILD's 10-Q
Source: 10-Q filed 2026-05-07 · compared against 10-Q 2025-11-07. Every passage below is quoted verbatim from the filing itself.
Strategy & Outlook
This filing
expect to record related charges of approximately $11.5 billion to Acquired in-process research and development expenses in the second quarter of 2026, which we expect to result in a net loss for the second quarter and full year 2026.
Product Sales
This filing
HIV product sales increased 10% to $5.0 billion
Legal Proceedings
This filing
As of September 30, 2025, we had approximately $242 million of accruals... with approximately $200 million accrued for a settlement... that we entered into in April 2025 and paid subsequently.
Balance Sheet & Liquidity
This filing
In February 2025, we repaid $1.75 billion of principal balance
What it means — the analyst reading
The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.
See the Filing Change Monitor →Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.